Literature DB >> 11060321

Lynch syndrome: genetics, natural history, genetic counseling, and prevention.

H T Lynch1, J Lynch.   

Abstract

Lynch syndrome is the most common hereditary form of colorectal cancer (CRC). Its natural history has been investigated extensively, so that highly targeted surveillance and management strategies, melded to its natural history, have proven effective in cancer control. Most important is the early age of onset of cancer (approximately 44 years), involving CRC and the several extracolonic cancers that are integral to the syndrome. With respect to CRC, approximately 70% of cases occur proximal to the splenic flexure. Synchronous and metachronous CRCs are extremely common. Full colonoscopy should be initiated when the patient is between the ages of 20 and 25, and because of the accelerated carcinogenesis of CRC, it should be performed every 1 to 2 years. The presence of initial CRC requires subtotal colectomy, given the mentioned increased frequency of metachronous cancer. Options available for germ-line mutation carriers, in addition to cancer screening, include prophylactic colectomy as well as prophylactic total abdominal hysterectomy and bilateral salpingo-oophorectomy. The discovery of mismatch repair germ-line mutations (most commonly MSH2 or MLH1) has added significantly to the recognition of this disease as well as to the search for high-risk individuals throughout families who, with genetic counseling, may become candidates for germ-line mutation testing. Clearly, hereditary nonpolyposis colorectal cancer provides an excellent opportunity for learning about the etio-pathogenesis of cancer at the molecular and clinical levels and how this knowledge might ultimately be exploited for cancer control. A search for chemoprevention agents, such as cyclo-oxygenase 2 inhibitors, as well as for putative environmental effects and how they may interact with the genetic component in CRC etiology should abet this entire cancer control process.

Entities:  

Mesh:

Year:  2000        PMID: 11060321

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  26 in total

1.  Is genetic screening for the Lynch syndrome effective?

Authors:  Aleksandra Misak
Journal:  CMAJ       Date:  2005-06-07       Impact factor: 8.262

2.  Balancing life with an increased risk of cancer: lived experiences in healthy individuals with Lynch syndrome.

Authors:  Helle Vendel Petersen; Mef Nilbert; Inge Bernstein; Christina Carlsson
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

3.  New genetic variants of genes MMR in a Spanish family with Lynch syndrome.

Authors:  J L Martín Ruiz; M J Alvarez-Cubero; J Fernandez Rosado; E Martinez Espín; C Entrala Bernal
Journal:  Int J Colorectal Dis       Date:  2012-12-08       Impact factor: 2.571

4.  Screening of hub genes and pathways in colorectal cancer with microarray technology.

Authors:  Yonggang Wang; Tianying Zheng
Journal:  Pathol Oncol Res       Date:  2014-02-07       Impact factor: 3.201

Review 5.  Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.

Authors:  J Stuart Ferriss; M Yvette Williams-Brown
Journal:  Curr Treat Options Oncol       Date:  2019-08-23

6.  Role of detection of microsatellite instability in Chinese with hereditary nonpolyposis colorectal cancer or ordinary hereditary colorectal cancer.

Authors:  Wen-Zhi Liu; Feng Jin; Zhen-Hai Zhang; Shu-Bao Wang
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

7.  Characterization of pathogenic human MSH2 missense mutations using yeast as a model system: a laboratory course in molecular biology.

Authors:  Alison E Gammie; Naz Erdeniz
Journal:  Cell Biol Educ       Date:  2004

8.  Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.

Authors:  Eva Wielders; Elly Delzenne-Goette; Rob Dekker; Martin van der Valk; Hein Te Riele
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

9.  Lynch syndrome (HNPCC).

Authors:  Józef Kladny; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

10.  MUTYH Associated Polyposis (MAP).

Authors:  M L M Poulsen; M L Bisgaard
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.